The Patent Finder

Italfarmaco S.p.A.

12 patents currently held · Updated Nov 17, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

4
Ending by 2030
Oct 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Sep 17, 2027
    The maintenance fee for Benzo-N-hydroxy amide compounds having antitumor activity (US 10,590,101) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,522,127Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,937,152Non-selective somatostatin analogues
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,765,150Riluzole aqueous suspensions
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,217,079Method for treating Philadelphia-negative myeloproliferative syndromes
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,421,184Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,867,799Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,688,047Physically and chemically stable oral suspensions of givinostat
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,745,696HC-CDR3-only libraries with reduced combinatorial redundancy and optimized loop length distribution
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,590,101Benzo-N-hydroxy amide compounds having antitumor activity
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,351,178Selective HDAC6 Inhibitors
In force
 · High confidence
In forceHigh confidence
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents
Also on record, not counted in the 12: 3 patents in force now held by others · 5 lapsed for an unpaid fee · 33 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 9 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited